The biopharma sector continues to experience substantial workforce reductions in 2025, with 62 layoff rounds reported in the third quarter alone—nearly matching the 64 rounds recorded in each of the first two quarters. Notable contributors include Novo Nordisk, which announced 9,000 job cuts, and Merck & Co., planning to eliminate 6,000 positions as part of cost-saving measures. Sarepta Therapeutics also carried out a 36% staff reduction alongside strategic pipeline refocusing. These layoffs highlight ongoing operational shifts and financial pressures across large and midsize biopharma companies.